Detection of nasopharyngeal carcinoma in Morocco (North Africa) using a multiplex methylation-specific PCR biomarker assay by unknown
Nawaz et al. Clinical Epigenetics  (2015) 7:89 
DOI 10.1186/s13148-015-0119-8RESEARCH Open AccessDetection of nasopharyngeal carcinoma in
Morocco (North Africa) using a multiplex
methylation-specific PCR biomarker assay
Imran Nawaz1,2†, Khalid Moumad3,4†, Debora Martorelli5, Moulay Mustapha Ennaji6, Xiaoying Zhou1,7, Zhe Zhang7,
Riccardo Dolcetti5, Meriem Khyatti4, Ingemar Ernberg1 and Li-Fu Hu1*Abstract
Background: Silencing of tumor suppressor genes (TSGs) or activation of oncogenes by, e.g., aberrant promoter
methylation, may be early events during carcinogenesis. The methylation status of such genes can be used for early
detection of cancer. We are pursuing this approach in our efforts to develop markers for early detection and follow-up
of nasopharyngeal carcinoma (NPC). We set out to develop this approach to allow identification of NPC from Morocco
and then also compared with NPC samples from different geographical locations and different ethnicity with different
NPC incidences, Epstein-Barr virus (EBV) prevalence, and environments.
Results: By multiplex methylation-specific PCR (MMSP), multiple relevant genes can be detected simultaneously, to
achieve high sensitivity and specificity. The strong association of EBV with NPC is also very useful in such an approach.
We have initially screened for 12 potential marker genes including EBV genes coding for EBV nuclear antigen 1
(EBNA1) and latent membrane protein-1 (LMP1) and ten potential TSGs obtained from previously published data. The
resulting assay included EBNA1, LMP1, and three cellular TSGs: ITGA9, RASSF1A, and P16. We evaluated this assay on 64
NPC patient biopsies from Morocco, Italy, and China compared to deoxyribonucleic acid (DNA) from 20
nasopharyngeal control tissues. In the Moroccan NPC cohort (n = 44), prevalence of the EBNA1 gene showed the
highest sensitivity (36/44; 82 %) with 94 % specificity. Out of eight (18 %) EBNA1 negative Moroccan samples, only
three were positive for at least one methylated cellular gene. By detection of cellular marker genes, the sensitivity
increased from 82 to 89 % (39/44). In the whole material of 64 biopsies from three geographical locations, at least any
one marker (viral or cellular) could be detected in 91 % of biopsies with 90 % specificity. In a pilot evaluating assay
performance on serum DNA from NPC and controls including samples from Italy (n = 11) and China (n = 5), at least
any one marker from the MMSP assay could be detected in 88 %, but the specificity was only 50 %.
Conclusions: An MMSP assay has the potential for detection of NPC by screening in high-risk populations.
Serum-derived DNA seems not as good as earlier published NPC swab DNA for screening purpose.
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Nasopharyngeal carcinoma (NPC) is a malignant tumor
that arises in the mucosal epithelium of the posterior wall
of the nasopharynx [1]. Its clinical presentation, epidemi-
ology, and histopathology are different from other squa-
mous cell carcinomas of the head and neck [2]. NPC has a
marked ethnic and geographic distribution. Specifically, its
most common form, World Health Organization (WHO)
type III, is highly prevalent in southern China, Southeast
Asia, North Africa, and Greenland and is strongly associ-
ated with the Epstein-Barr virus (EBV) [3–7]. In Morocco,
NPC is the most frequent tumor of the head and neck
region accounting for 7–12 % of all cancers in men [8, 9].
Interestingly, NPC has also been reported to be the most
common neoplasia of the nasopharynx and respiratory
tract in children in Morocco and Tunisia accounting for
5–20 % of childhood malignancies [10, 11, 9]. This is even
higher than its incidence in the high endemic NPC areas
in China, where it is 0.1 % in children [12, 13]. Differences
in NPC incidence are also reported in the same geograph-
ical locations between members of different ethnic groups
[14, 15]. Certain dietary habits such as consumption of
salted fish and preserved food containing volatile nitrosa-
mines are also reported to play some role in the etiology
of NPC [16–18]. Regardless of incidence and geographical
distribution, its development has been attributed to an
interaction of multiple factors: environmental including
EBV infection and genetic factors [19, 20]. Chromosomal
abnormalities and aberrant promoter hypermethylation
show a similar pattern in different geographical regions
according to one study so far, supporting a common car-
cinogenic pathway to NPC irrespective of region [21].
Approximately 70 % of NPC is diagnosed in advanced
stages when treatment results are unsatisfactory. This is
largely due to the non-specific local symptoms [3, 22–24].
Diagnosis of NPC at stages I or II is associated with a high
survival rate (on average 95 %), whereas the survival rate
is just above 50 % when diagnosis is made late at stages III
or IV [25]. Because of a higher cure rate for early-stage
NPC, the concept of screening for the disease has an
intuitive appeal. Further development of therapies is ne-
cessary but not sufficient to improve the survival of NPC
patients [26]. The development of reliable, non-invasive,
and cost-effective early-detection methods for NPC is a
high priority. Application of tumor markers thus provides
a relevant approach to achieve early detection of NPC.
The rapid acquisition of fully sequenced cancer genomes
will be one powerful tool to identify biomarker candidates
for early detection, subtyping, and cancer screening [27].
It has been suggested that cancer can be initiated by
epigenetic changes before any mutations take place. This
epigenetic progenitor hypothesis is supported by experi-
mental data on, e.g., colon cancer [28]. This makes epi-
genetic marks highly interesting for early diagnosis ofcancer [29, 30]. In the case of NPC, latent EBV infection
may drive epigenetic changes in normal epithelial cells
to promote tumorigenesis [31]. But genetic alterations
including deoxyribonucleic acid (DNA) methylation of
cyclin-dependent kinase inhibitor 2A (P16) and RASSF1A
loci have been reported to occur in premalignant nasopha-
ryngeal epithelium even prior to EBV infection [32]. Aber-
rant methylation of tumor suppressor genes (TSGs), e.g.,
P16, is a frequent event in NPC [33]. DNA methylation also
plays an important role in the maintenance of specific EBV
latency programs in the NPC cells [34, 31, 35]. Aberrant
methylation of both viral and cellular genes may thus be
involved in the transformation and progression of nasopha-
ryngeal epithelial cells into malignant ones [36–38]. Screen-
ing for DNA hypermethylated marker genes, e.g., TSGs,
has a great potential to be used as an assay for early detec-
tion of NPC [39]. Moreover, the EBV-host epigenetic inter-
play and the reversible nature of epigenetic mechanism of
gene regulation in NPC make such genes interesting also in
the context of NPC therapy and prevention [40–42].
Recently, it was demonstrated that gastric carcinoma asso-
ciated with EBV is strongly hypermethylated (as a whole
tumor subgroup) compared to EBV-negative gastric carcin-
oma [43–45].
Several techniques for analyzing DNA methylation status
have been developed, each one with advantages and limita-
tions. As an example, methylation-specific PCR (MSP)
allows detection of one methylated gene copy among 1000
unmethylated copies [46] but it can only be applied to one
gene at a time. For high-throughput methylation studies,
state-of-the-art equipment and qualified bioinformatics are
required. Until now, this makes such techniques unsuitable
at the clinical level [47]. Due to this, we previously devel-
oped a simple and rapid PCR-based assay designated
multiplex methylation-specific PCR (MMSP) which could
detect the methylation status of multiple markers in a
single reaction simultaneously [48].
When applied to samples from regions with a lower
NPC risk than China like Morocco, North Africa (medium
risk), its performance decreased, and thus, we tried to
modify the assay to obtain good specificity and sensitivity
for tumors in such areas. This modified MMSP assay
includes, as before, prevalence of the EBV nuclear antigen
1 (EBNA1) (not methylated), important for distinguishing
between EBV-positive and EBV-negative subtypes of NPC
or non-cancerous control samples. The expression level of
EBV-encoded latent membrane protein-1 (LMP1), which
is an EBV oncoprotein, expressed in approximately 65 % of
EBV-positive NPC patients and was regulated by promoter
methylation [49]. Outcome of LMP1 in the MMSP panel
would reflect LMP1-expression status. In addition to the
EBV genes, three TSGs namely integrin, alpha 9 (ITGA9);
Ras association (RalGDS/AF-6) domain family member 1
(RASSF1A); and P16 were included after screening the
Table 1 Sensitivity and specificity of markers in DNAs from NPC
samples (n = 44) and non-cancerous controls (n = 18) from
Morocco using MSP
Marker gene Sensitivity %a Specificity %b
EBNA1 82 (36/44) 94 (17/18)
U-LMP1 59 (26/44) 94 (17/18)
M-RASSF1A 66 (29/44) 94 (17/18)
M-DAPK 25 (11/44) 72 (13/18)
M-ITGA9 50 (22/44) 100 (18/18)
M-P16 45 (20/44) 100 (18/18)
M-WNT7A 69 (11/16) 80 (4/5)
M-CHFR 40 (16/40) 67 (4/6)
M-CYB5R2 47 (17/36) 75 (6/8)
M-WIF1 100 (10/10) 25 (2/8)
M-RIZ1 0 (0/4) 100 (3/3)
M-FSTL1 57 (4/7) 67 (6/9)
aSensitivity = number of positive cases in NPC patients/total number of NPC
cases tested
bSpecificity = (total number of tested non-cancerous controls− number of positive
cases in tested non-cancerous controls)/total number of tested
non-cancerous controls
Table 2 Comparison of sensitivity and specificity of DAPK and
combination of ITGA9 and P16 (where either or both of them
were methylated) on NPC samples (n = 44) and non-cancerous
controls (n = 18) from Morocco
Marker gene Sensitivity Specificity
M-DAPK 25 % (11/44) 72 % (13/18)
M-ITGA9/M-P16 70 % (31/44) 100 % (18/18)
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lished data (including our own; ITGA9; RASSF1A; P16;
death-associated protein kinase (DAPK); wingless-type
MMTV integration site family, member 7A (WNT7A);
checkpoint with forkhead and ring finger domains (CHFR);
cytochrome b5 reductase 2 (CYB5R2); WNT inhibitory
factor 1 (WIF1); PR domain containing 2, with ZNF do-
main (RIZ1); and follistatin-like 1 (FSTL1)) on NPC tumor
biopsies and evaluating their individual sensitivity and
specificity.
MMSP allows analyses of the methylation status of
multiple genes in a single reaction. This is cost-effective
and could be suitable for detection of NPC in patients
from different geographical, environmental, and genetic
backgrounds and of different subtypes (e.g., EBV-
positive or EBV-negative). Early detection will be an in-
strumental step improving therapeutic results. For this,
invasive biopsy sampling will not be suitable on a large
scale so less invasive sources of DNA have to be sought.
We earlier evaluated nasopharyngeal secretions (swabs)
and now made a small pilot evaluating the assay per-
formance on serum DNA from NPC and controls. How-
ever, specificity was rather low in serum and one can
question its representation of tumor specificity. Thus,
NPC swab DNAs are to be preferred while using serum-
derived DNA could possibly be improved.
Results
Identification of additional candidate methylated markers
for NPC using MSP
All the DNAs from the NPC and normal biopsy samples
from Morocco were screened using MSP for 12 markers
(including the markers used in the MMSP assay published
previously [48] comprising EBNA1, LMP1, RASSF1A, and
DAPK but also 8 new markers including ITGA9, P16,
WNT7A, CHFR, CYB5R2, WIF1, RIZ1, FSTL1). The re-
sults are summarized in Table 1. Of the Moroccan sam-
ples, 36/44 (82 %) were positive for EBNA1 while the
remaining 8 samples (18 %) were negative. This result on
Moroccan NPC patients differed from that of southern
China where the common type of undifferentiated NPC is
strongly associated with EBV [15, 50–57]. RASSF1A was
positive in 29/44 as the most sensitive marker (66 %) after
EBNA1. Among the previously published MMSP assay
marker genes, DAPK showed the lowest sensitivity 11/44
(25 %) in Moroccan NPC DNA samples, and the specifi-
city was 13/18 (72 %) when comparing to non-cancerous
nasopharyngeal epithelium from the same geographic lo-
cation. These results motivated an effort to replace DAPK
with a marker with higher sensitivity and specificity. Eight
genes were selected from published literature and screened
on NPC samples and controls from Morocco. ITGA9 and
P16 were the two with the highest specificity (100 %) and
better sensitivity than DAPK (Sn 22/44, 50 % and Sn 20/44,45 %, respectively). From these results, it was apparent, as
expected, that a single gene cannot be used for screening/
early detection. Therefore, we set out to explore combina-
tions of several genes and modify our previously published
MMSP assay to improve it so that it could be applied on
samples from different geographical locations, including
also EBV-negative NPC.
A comparison of sensitivity and specificity of DAPK
with a combination of ITGA9 and P16 (where either or
both of them were methylated) showed an increase in
sensitivity and specificity (Table 2). Either ITGA9 (n = 11)
or P16 (n = 9) or both (n = 11) were methylated in 70 %
(31/44) DNA samples from Morocco with 100 % (18/18)
specificity.Development of modified multiplex methylation-specific
PCR and screening NPC biopsy and control samples from
Morocco
On the basis of MSP results, a modified MMSP assay
was developed which comprised EBNA1 and LMP1 as
before, but DAPK was replaced with ITGA9 and P16
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housekeeping gene β-ACTIN as DNA-control was used
alternatingly with glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) as internal loading controls and quality
controls for bisulfite conversion of DNA. The modified
MMSP was used to screen 64 NPC patient biopsies with
16 corresponding serum samples from Morocco, Italy,
and China compared to DNA from 20 nasopharyngeal
tissues and 8 serum samples from persons without cancer.
We first analyzed only the 36 EBNA1 positive NPC
samples from Morocco (Fig. 1). The marker gene pattern
in NPC DNA was clearly different from that of non-
cancerous controls. In the EBNA1 positive samples,
RASSF1A was detected in 28/36 and thus was the most
sensitive marker (78 %). Marker genes ITGA9 and P16
showed 56 and 50 % sensitivity, respectively, but both of
them were 100 % specific. The MMSP results in the
EBNA1 positive samples are summarized in Table 3.
In Table 4, we show the co-occurrence of methylated
marker genes in the EBNA1 positive samples with our
MMSP marker panel (i.e., RASSF1A, LMP1, ITGA9, and
P16). The majority of the NPC biopsies were positive for
more than one marker in addition to EBNA1. No meth-
ylated marker gene could be detected in one EBNA1
positive NPC sample (3 %). The remaining NPC samples
(97 %; 35/36) were positive for at least any one marker
in addition to EBNA1, whereas all but one (17/18; 94 %)
of the non-cancerous samples were negative with the
criterion of EBNA1 plus at least one methylation marker.
The sensitivity and specificity with at least any two
markers were, respectively, 83 and 94 % that is also ap-
plicable for such an assay. The positive predictive value
(PPV) and negative predictive value (NPV) in samples
from Morocco were 97 and 94 %, respectively.
EBV EBNA1 could not be detected in 18 % (8/44) of
our NPC biopsy samples from Morocco. These areFig. 1 MMSP assay applied to DNAs from NPC tissue and non-cancerous c
Namalwa was used as a positive control (see the “Methods” section) as foll
and Namalwa DNA in 1:2 ratio. Water was used as a blank control. T NPC trepresentatives of subtypes of NPC most commonly
found in the non-endemic regions, e.g., in Europe and
USA. Only in three out of these eight EBNA1 negative
NPC biopsy samples could we detect at least one meth-
ylated cellular marker gene. One sample showed methyl-
ated ITGA9, another one P16, and the third methylated
ITGA9, P16, and RASSF1A. Taken together, irrespective
of EBNA1 status, 89 % (39/44) of Moroccan samples
were positive with at least any one positive viral or cellu-
lar marker.
Analyzing tumors and sera from Chinese and Italian NPC
and controls with modified MMSP
We applied the MMSP to a subset of our samples irre-
spective of EBNA1 status including two independent
small cohorts from China and Italy on tumor DNA sam-
ples with paired matched serum samples (Table 5). One
hundred percent (5/5) of tumor DNA from tumor and
80 % (4/5) of corresponding NPC sera were positive in
Chinese samples (Fig. 2). In the Chinese cohort, we had
control DNA only from two biopsies, and one of them
was negative for all the MMSP markers. In DNA sam-
ples from Italy, we could identify 93 % (14/15) as NPC
with at least any one MMSP marker (Fig. 3). Ninety-one
percent (10/11) of serum samples from Italy were posi-
tive as NPC-related. In the Italian cohort, we also had
eight control DNA samples from sera. The specificity
among these samples was also as low as 50 %. Remarkably,
the pattern of MMSP markers observed in biopsy samples
did not match with the patterns found in the correspond-
ing serum samples from both China and Italy.
We tested the modified MMSP assay on DNAs from
64 NPC biopsies from three different geographical re-
gions (Morocco 44, Italy 15, and China 5), 16 corre-
sponding NPC sera (Italy 11 and China 5), 20 control
biopsies (Morocco 18 and China 2), and 8 control seraontrol from Morocco. A mixture of cell line DNA from CNE1 and
ows: P1: 40 ng CNE1 and Namalwa DNA in 1:2 ratio; P2: 5 ng CNE1
issue, N non-cancerous controls
Table 3 Sensitivity and specificity of markers in EBNA1 positive
NPC samples (n = 36) and non-cancerous controls (n = 18) from
Morocco using modified MMSP assay
Marker gene Sensitivity %
(positive cases/total)
Specificity % (total
cases − positive cases/
total control cases)
U-LMP1 72 (26/36) 94 (17/18)
M-ITGA9 56 (20/36) 100 (18/18)
M-RASSF1A 78 (28/36) 94 (17/18)
M-P16 50 (18/36) 100 (18/18)
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least one marker in 91 % (58/64) at 90 % (18/20) specifi-
city. In the smaller cohort of serum samples, at least one
marker could be detected in 88 % (14/16) of the samples
at 50 % (5/10) specificity.
Discussion
The unique features of NPC, its regional incidence, and
its strong association with EBV [58] have led to an in-
tense effort to establish the role of EBV in its pathogen-
esis, to find possible susceptibility genes and regional
environmental factors that could lead to improved diag-
nosis, treatment, prognostic tools, and possibly preven-
tion. Well over a 100 cellular genes and several EBV
genes have been implicated in the disease progression.
The number of genes deregulated by epigenetic mecha-
nisms, primarily promoter methylation, is steadily
growing.
Our present knowledge of cancer genomes can be
translated into improved methods to reduce cancer inci-
dence and related deaths [27]. A panel of three to four
marker genes could define an abnormality in 70–90 % of
each cancer type studied by detection of their aberrantTable 4 Different combinations of modified MMSP markers observe
(EBNA1)-positive (n = 36) and non-cancerous controls (n = 18) from M
Marker genes/combinations 1 2 3
EBNA1 + + + +
U-LMP1 - + - +
M-ITGA9 - - - +
M-RASSF1A - - - -
M-P16 - - + -
NPC samples (n = 36) 1 4 1 2
Control (n = 18) 0 0 0 0
EBNA1 + at least 3 methylation markers
EBNA1 + at least 2 methylation markers S
S
EBNA1 + at least 1 methylation marker Sn: 97 % (35/36)
Sp: 94 % (17/18)methylation [59]. It has also been observed that the EBV
methylome in EBV-positive cancer cells is significantly
different compared to that of EBV-carrying cells repre-
senting non-tumorigenic human B-cell-derived lympho-
blastoid cell lines [59]. Thus, epigenetic signatures from
both human cellular genes and EBV genes may pose an
ideal combination to detect NPC or discriminate NPC
from malignancies of other origins [60]. A combination
of methylation-regulated TSGs including RASSF1A, P16,
and EBV-based markers could serve as a complementary
test for the early detection of NPC [47, 61].
Based on our MMSP results on all the 44 NPC sam-
ples from Morocco, five different patterns were seen:
only EBNA1 positive; EBNA1 + LMP1 positive; positive
for any methylated TSG, i.e., RASSF1A, ITGA9, or P16;
EBNA1 negative; and negative for all MMSP markers
and EBNA1. In this study, 36/44 (82 %) Moroccan NPC
samples were positive for EBNA1. Among eight EBNA1
negative samples, five samples (11 %) were negative for
all MMSP markers except DNA control GAPDH. The
prevalence of EBV in NPC has been reported to differ
between different geographical locations, in China 100 %
[48], Indonesia 92.5 % [47], and Tunisia 100 % [61]. In
Europe and the US, the prevalence of EBV-positive cases
is much lower, estimated to 5–10 %, and these NPCs are
mostly WHO type I. EBV may act as an epigenetic driver
in NPC tumorigenesis [34] by genome-wide hyperme-
thylation [62, 63]. EBV-negative NPC has been reported
to show lower frequencies of TSG promoter hyperme-
thylation as compared to EBV-positive NPC [34]. In our
case, the prevalence of EBV in NPC samples from
Morocco was 82 %. Among the EBNA1 negative samples
(n = 8), methylated DAPK was not detected, but one
sample was positive only for P16 and another suchd in NPC samples selected on the basis that they were EBV
orocco
4 5
+ + + + + + +
+ - - + + - +
- + - + - + +
+ + + + + + +
- - + - + + +
3 2 2 6 5 4 6
1 0 0 0 0 0 0
Sn: 58 % (21/36)
Sp: 100 % (18/18)
n: 83 % (30/36)
p: 94 % (17/18)
Table 5 Comparison of sensitivity and specificity of previous and modified MMSP markers on DNAs from NPC and control samples
from Morocco, Italy, and China using at least any one viral or cellular marker (irrespective of EBNA1 status)
Origin DNA source Previous panel of markers Modified panel of markers
Sensitivity Specificity Sensitivity Specificity
Morocco Tumor 84 % (37/44) 67 % (12/18) 89 % (39/44) 94 % (17/18)
Italy Tumor 93 % (14/15) NA
Serum 91 % (10/11) 50 % (4/8)
China Tumor 100 % (5/5) 50 % (1/2)
Serum 80 % (4/5) NA
Total Tumor 84 % (37/44) 67 % (12/18) 91 % (58/64) 90 % (18/20)
Serum 88 % (14/16) 50 % (4/8)
NA not applicable
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sample was positive for ITGA9, RASSF1A, and P16.
These samples might represent EBV-negative NPC. The
possibility of diagnostic errors or non-representative
sampling in the EBV-negative NPC cannot be excluded.
Nevertheless, at least any one viral or cellular marker of
modified MMSP could be detected in 89 % of all cases
from Morocco.
Applying the previously published MMSP panel of
markers on all the Moroccan NPC samples (irrespective
of EBNA1 presence or absence), at least any one marker
could be detected positive in 84 % (37/44) with 67 % (12/
18) specificity. In the previous publication, the sensitivity
was 98 % (48/49) with 100 % (20/20) specificity when the
assay was applied on Chinese NPC. This difference in
the sensitivity and specificity of the same panel of
markers might be due to differences in ethnicity, envir-
onmental factors, and EBV infection rates between
these geographical regions. With the new, modified
MMSP applied on the Moroccan samples, any one
positive marker could be detected in 89 % (39/44) with
94 % (17/18) specificity (Table 5).
DNA coding for EBNA1, the nuclear household pro-
tein of EBV, was used as a marker for EBV prevalence.Fig. 2 MMSP assay applied to DNAs from matched NPC tissue and serum
used as a positive control as follows: P1: 40 ng CNE1 and Namalwa DNA in
CNE1 and Namalwa DNA in 1:2 ratio. Water was used as a blank control. TAs the part of the EBNA1 gene amplified by PCR is
present only once in an EBV genome, it has the potential
of quantifying EBV DNA load in, e.g., NPC swab or
serum, using a one/haplome EBV-positive cell as refer-
ence (Namalwa). Few malignancies express the EBV-
encoded oncoprotein, LMP1. The LMP1 primers used in
the assay specially amplified bisulfite-converted unmethy-
lated alleles. Judging the LMP1 methylation status in a
specific NPC adds to the specificity of the MMSP and po-
tentially provides information about the prognosis of
NPC, known to be affected by LMP1 [49]. Out of 36
EBNA1 positive NPC samples, 26 samples (72 %) were
also positive for unmethylated LMP1 which is quite con-
sistent with our previous study (Table 3) [49].
The primers for ITGA9, RASSF1A, and P16 were de-
signed to amplify methylated alleles only. Among these,
ITGA9 is a component of the α9β1 integrin receptor
that plays an integral role in different signal transduction
pathways controlling cellular proliferation and differenti-
ation. In ITGA9 knockout mice, abnormal proliferation
and differentiation of keratinocytes suggest its role in
these cellular processes [64]. Here, we showed that ITGA9
is methylated in NPC. RASSF1A is also a strong candidate
TSG for NPC. The RASSF1A protein could interact withfrom China. A mixture of cell line DNA from CNE1 and Namalwa was
1:2 ratio; P2: 10 ng CNE1 and Namalwa DNA in 1:2 ratio; P3: 5 ng
NPC tissue, S serum
Fig. 3 MMSP assay applied to DNAs from matched NPC tissue, serum, and non-cancerous serum from Italy. A mixture of cell line DNA from CNE1
and Namalwa was used as a positive control as follows: P1: 40 ng CNE1 and Namalwa DNA in 1:2 ratio; P2: 5 ng CNE1 and Namalwa DNA in 1:2
ratio. Water was used as a blank control. T NPC tissue, S serum, NS non-cancerous serum
Nawaz et al. Clinical Epigenetics  (2015) 7:89 Page 7 of 12DNA repair system and also induce cell-cycle arrest. It has
been shown to be frequently methylated in NPC biopsies,
and the aberrant methylation is tightly correlated with loss
of expression of RASSF1A in NPC [65, 66]. P16 inactivates
the cyclin D-cyclin-dependent kinase 4 (or 6) complex
resulting in the inactivation of retinoblastoma protein and
thus blocks the transcription of important cell-cycle regu-
latory proteins and results in cell-cycle arrest. It is a major
target in tumorigenesis and is altered in multiple primary
tumors [67]. Promoter hypermethylation of P16 is fre-
quent in NPC [68, 69]. Most importantly, the loss of P16
may be an early event in cancer progression [67] which
made P16 a good candidate for our MMSP assay.
The strong association of EBV with undifferentiated
NPC prevalent in high-endemic areas makes EBV a good
marker for screening in a high-risk population. However,
EBV-based markers are not enough for identification of
NPC types that are not associated with EBV, which are
found in intermediate and prevalent in low-risk areas.
The inclusion of cellular marker genes in an assay like
MMSP will be very important for identifying EBV-negative
NPC cases. EBNA1 was not detected in 14 % (8/44) of our
biopsy samples from Morocco. In three out of these eight
samples, we could detect the methylation of at least any
one methylated cellular gene. This shows the importance
of cellular genes in the MMSP assay for the identification
of EBV-negative samples but also that we had been unable
to find the most suitable marker genes for such cases.
Alternatively, the five totally negative biopsies might have
been non-representative of NPC. In future studies, such
results demand further validation by pathology. The pres-
ence of cellular TSGs in the MMSP assay increased the
sensitivity of the assay from 84 to 89 % without affecting
the specificity (94 %).
The low level of EBV DNA persists throughout life in
infected B cells in all blood-perfused tissues of EBV-infected people (i.e., more than 90 % of the adult popula-
tion globally) [70, 71]. The low level of EBV DNA is also
found in saliva in some of these healthy carriers. Detec-
tion of EBV DNA, e.g., with the EBNA1 gene, thus poses
a slight risk of false positives using nasopharyngeal
swabs, saliva, blood, plasma, and even serum. The levels
are usually so low that they end up below cutoff also in
regular PCR assays. This is an additional argument why
one should not only rely on EBV genes in future screen-
ing protocols. In this study, we could identify 84 % (10/
11) of NPC with only 50 % (5/10) specificity when sera
were used as a DNA source. This might be because the
serum contains few circulating tumor cells (CTCs) and
cell-free tumor DNA (cftDNA) while the majority of the
cells in the serum are lymphocytes. The possibility of
using serum for the early detection of cancer can im-
prove with improvements of CTC and cftDNA isolation
and enrichment. With high-throughput (HTP) methods
for the isolation or enrichment of CTC or cftDNA, spe-
cificity and sensitivity might be improved for serum
samples. Our earlier work showed that DNA swabs with
nasopharyngeal secretion were a much better source of
DNA for screening EBNA1 and at least any one add-
itional marker could be detected in 98 % (48/49) samples
with 100 % specificity, which is good as it is a totally
non-invasive method.
Although methylation levels of DAPK differed clearly
between the Chinese and the Moroccan/Italian samples,
we did not observe any additional obvious differences in
the methylation patterns between samples from different
geographical locations with the current MMSP panel.
The Italian and the Chinese samples showed a similar
level of MMSP positivity for cellular markers as the
Moroccan ones. Thus, an MMSP panel can be applied
to samples from different geographical locations with
different NPC subtype distribution.
Nawaz et al. Clinical Epigenetics  (2015) 7:89 Page 8 of 12As pattern and timing of methylation status in specific
genes are associated with defined biological behaviors
[72], we believe that the MMSP method will not only
provide diagnostic information but has the potential of
predicting behavior of individual tumors, as part of fu-
ture personalized medicine. Monitoring EBV load and
methylation levels of specific genes have been shown to
be useful for monitoring disease relapse after treatment,
suggesting that MMSP may serve as a way of outcome
follow-up after NPC treatment.
It will be meaningful to extend the application of the
MMSP assay for the diagnosis of other types of cancer by
establishing MMSP patterns with a different panel of
marker genes on (tumor) DNA from body fluids, such as
detection of prostate cancer or bladder cancer with DNA
from urine, cervical cancer by cervical swab, or lung cancer
by sputum or blood.
Conclusions
MMSP can be useful for detection of NPC by a single
reaction using a small amount of DNA. It could be devel-
oped into a robust, specific, sensitive, and cost-effective
screening technique. If applied to nasopharyngeal swabs,
or possibly blood/serum, it can be used for the early detec-
tion of NPC in high-risk populations. The method is easy
to manage in a clinical setting and requires only routine
small equipment. Further studies are required to validate
the feasibility of the MMSP assay as a population-based
screening tool in NPC high-risk populations as well as a
way of monitoring tumor recurrence. Detection of the
methylation of specific genes has the potential not only to
provide diagnostic information but also to provide infor-
mation about the specific behavior of individual tumors,
which could direct diagnostic, preventive, and even thera-
peutic strategies. Unfortunately, we were unable to dem-
onstrate any feasibility to use serum for the detection of
NPC-specific DNA, although the pilot cohort was very
small. We showed earlier that nasopharyngeal swabs could
be used for this purpose with both better performances.
Thus, our modified MMSP assay should also be evaluated
on DNA from nasopharyngeal swabs for NPC detection.
Methods
Cell lines and clinical samples
Human cell line DNA of CNE1 (EBV negative, NPC [73])
and Namalwa (EBV positive, latency III, Burkitt lymphoma
[74, 75]) were cultured in RPMI 1640 medium (Gibco® by
life technologies) containing 10 % fetal calf serum (FCS) at
37 °C with 5 % CO2. Namalwa has two copies of EBV gen-
ome/cell [76]. These two cell lines were used as a positive
control for this semi-quantitative methylation PCR. DNA
from 44 biopsies from pathology-verified NPC patients and
18 non-cancerous volunteers were obtained from Institut
Pasteur du Maroc, Casablanca, Morocco, in the year 2011(ethical approval: No. 00-302, Stockholm, Sweden, and
2010-02-15, Casablanca, Morocco). Out of 44 NPC sam-
ples, 36 samples were positive for EBNA1 whereas 8 sam-
ples were EBNA1 negative. In 36 EBNA1 positive samples,
27 were male while 9 were females. The average and me-
dian age of the EBNA1 positive patients was 45 and
50 years, respectively, ranging between 12 and 78 years.
The average age of control donors was 26 years. Out of 36
EBNA1 positive samples, 34 were of NPC type III. NPC
DNA samples from 13 matched biopsies and serum sam-
ples from pathology-verified NPC patients and additional
serum samples from 20 non-cancerous volunteers were
obtained from Italy in the year 2012 (ethical approval: No.
00-302, Stockholm, Sweden, and 2010-02-15, Casablanca,
Morocco). The samples were stored at −80 °C until fur-
ther use.
DNA extraction and conversion by bisulfite modification
DNA was extracted from cell lines, biopsies, and serum
and purified by conventional phenol/chloroform and
ethanol extraction method. Bisulfite conversion of the
DNA was performed by using EZ DNA methylation Kit
from Zymo Research (Cat#: D5002) following the proto-
col. CNE1 and Namalwa DNA were mixed in a 1:2 ratio,
respectively, to be used as a positive control.
Methylation-specific PCR (MSP)
For each PCR reaction, 4 microliters (μl; 40 nanogram
(ng)) of bisulfite-modified DNA was added in a final vol-
ume of 25 μl of PCR mixture containing 1.8× PCR buf-
fer, 5 millimolar (mM) magnesium chloride (MgCl2),
100 picomole (pmol) deoxynucleotide triphosphates,
primers (0.1 micromolar (μM) each per reaction), and
2.5 unit of Taq Platinum (Invitrogen). Water was used as
the negative control. The MSP primers used were taken
from the published data or were designed using the
MethPrimer software (Table 6) [77]. The primers for
EBNA1 localized inside the C-terminal coding region
[78] and were designed to amplify bisulfite-converted
EBV genome without distinguishing between methylated
and unmethylated CpGs. Primers for housekeeping gene
GAPDH served as a quality control for input DNA. This
marker could provide information if the bisulfite treat-
ment is complete and if the template is of good quality.
Primers for all other markers were inside the CpG-rich
promoter region. Primers for LMP1 were specific to amp-
lify unmethylated bisulfite-converted sequence. Primers
for all potential TSGs, i.e., ITGA9, RASSF1A, P16, DAPK,
WNT7A, CHFR, CYB5R2, WIF1, RIZ1, and FSTL1, were
designed to specifically amplify methylated bisulfite-
converted sequence. PCR amplifications were performed
at 95 °C for 3 min, followed by 4 cycles at 94 °C for 1 min,
60 °C for 30 s, and 65 °C for 45 s, which was then followed
by 36 amplification cycles at 94 °C for 1 min, 56 °C for
Table 6 Sequence of MSP primers used in the study
Marker Primer sequence (5′–3′) Size (bp) Refs
EBNA1 F AAGAGGTTTAGGAGTTTTAGTAGTTAGTTAT 130 a
R CACCTTCTTAATAATATTCAAAATAATC 130
U-LMP1 F GGGGGGATTTGTTTTTTTAATATAAATATAT 145 a
R TAAAATATAAACCCAAAAAAATTTACA 145
M-ITGA9 F GTTGTTGGTTCGGAGATTATATTTC 230 a
R AAAACAACCCGAATAAAAAACG 230
M-RASSF1A F GGGTTTTGCGAGAGCGCG 169 [79]
R GCTAACAAACGCGAACCG 169
M-P16 F CGAGTATTCGTTTACGGC 106 a
R CTTCCTCCGATACTAACG 106
M-DAPK F GGATAGTCGGATCGAGTTAACGTC 98 [79]
R CCCTCCCAAACGCCGA 98
M-CHFR F GTTTTAATATAATATGGCGTCGATC 213 a
R CTCAACTAATCCGCGAAACG 213
M-GAPDH F TTAGGTGGTTTTTTTTGATTTTAAT 192 a
R AAATTATCAAAACCCTTTTTCTAAACCAA 192
M-WNT7A F GTAGTTCGGCGTCGTTTTAC 123 [80]
R CGAAACCGTCTATCGATACG 123
M-CYB5R2 F GGGGAGCGGGTTAGTCGTC 140 [81]
R GAACCCGCAAACTCGTAACGTC 140
M-WIF1 F GGGCGTTTTATTGGGCGTATC 198 a
R TAACGAAACCAACAATCAACG 198
M-RIZ1 F ATTTTAGTTTTAGGGTGCGGTC 233 a
R AACTCCAATCGAAAATAACGTC 233
M-FSTL1 F TCGAGGTTGGCGATCGCG 171 [82]
R CGCAAACTCGCTCCGACCG 171
aPrimers designed in our lab using MethPrimer
Nawaz et al. Clinical Epigenetics  (2015) 7:89 Page 9 of 121 min, and 65 °C for 45 s. It was followed by a final elong-
ation step at 65 °C for 4 min. MSP products were analyzed
by 2.5 % agarose gel electrophoresis stained with ethidium
bromide.
Multiplex methylation-specific PCR
Based on our earlier data on the sensitivity and specificity
of several markers, we re-used EBNA1, LMP1, and
RASSF1A from the previous MMSP [48] but replaced
DAPK and CHFR with ITGA9 and P16. We also replaced
β-ACTIN with GAPDH to make the newer MMSP assay
suitable for both biopsy and serum samples. The EBNA1 is
not regulated by promoter methylation and distinguishes
between EBV-positive and EBV-negative samples. EBV-
encoded oncogenic LMP1—the main EBV transforming
protein in NPC—is expressed in 65 % of NPC patients, and
this is associated with its promoter methylation status
[49]. The presence of LMP1 in the MMSP panel of genes
would provide information about its expression status.The MMSP assay also includes the housekeeping gene
GAPDH that serves as a quality control for input DNA.
A 1:2 mixture of DNA from CNE1 (EBV negative, NPC)
and Namalwa (EBV positive, latency III, Burkitt lymph-
oma) was used as control, in order to get a positive signal
for all our marker genes. The MMSP assay also included
the housekeeping gene GAPDH as quality control of input
DNAs.
For each MMSP PCR reaction, 4 μl (40 ng) of bisulfite-
modified DNA was added in a final volume of 25 μg of
PCR mixture containing 1.8× PCR buffer, 5 mM MgCl2,
0.3 nM deoxynucleotide triphosphates, primers (ITGA9:
40 nM, GAPDH: 25 nM, RASSF1A: 40 nM, LMP1: 60 nM,
EBNA1: 30 nM, and P16: 100 nM per reaction), and 2.5
unit of Taq Platinum (Invitrogen). Water was used as the
negative control.
The primers and PCR conditions for MMSP amplifi-
cation and gel electrophoresis were the same as stated
for MSP.
Nawaz et al. Clinical Epigenetics  (2015) 7:89 Page 10 of 12Abbreviations
CHFR: checkpoint with forkhead and ring finger domains; CYB5R2: cytochrome
b5 reductase 2; DAPK: death-associated protein kinase; DNA: deoxyribonucleic
acid; EBNA1: EBV nuclear antigen 1; EBV: Epstein-Barr virus; FCS: fetal calf serum;
FSTL1: follistatin-like 1; GAPDH: glyceraldehyde-3-phosphate dehydrogenase;
ITGA9: integrin, alpha 9; LMP1: latent membrane protein-1; MgCl2: magnesium
chloride; mM: millimolar; MMSP: multiplex methylation-specific PCR;
MSP: methylation-specific PCR; ng: nanogram; NPC: nasopharyngeal carcinoma;
NPV: negative predictive value; P16: cyclin-dependent kinase inhibitor 2A;
pmol: picomole; PPV: positive predictive value; RASSF1A: Ras association
(RalGDS/AF-6) domain family member 1; RIZ1: PR domain containing 2, with
ZNF domain; RPMI: Roswell Park Memorial Institute medium; TSG: tumor
suppressor gene; WHO: World Health Organization; WIF1: WNT inhibitory factor
1; WNT7A: wingless-type MMTV integration site family, member 7A;
μl: microliter; μM: micromolar.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DM contributed reagents/materials/analysis tools. IE participated to conceive
the study, participated in the design of the study, participated in data
analyses, and helped to draft the manuscript. IN participated to conceive the
study, participated in the design of the study, performed the experiments,
analyzed the data, and drafted the manuscript. KM contributed reagents/
materials/analysis tools. LH conceived of the study, participated in its design,
contributed reagents/materials/analysis tools, coordinated, participated in
data analyses, and helped to draft the manuscript. MK conceived and
participated in the design of the study and contributed reagents/materials/
analysis tools. MME contributed reagents/materials/analysis tools. RD
contributed reagents/materials/analysis tools. XZ contributed reagents/
materials/analysis tools. ZZ contributed reagents/materials/analysis tools. All
authors read and approved the final manuscript.
Authors’ information
Imran Nawaz and Khalid Moumad contributed equally as first authors.
Acknowledgements
This study was supported by grants from Cancerfonden, Cancerföreningen in
Stockholm, National Natural Science Foundation of China (No. 81202135),
and a fellowship from the Project for the Development of University of
Balochistan, Quetta, Pakistan. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
”The work was supported by a grant from the Associazione Italiana per la
Ricerca sul Cancro, contract 14287 to RD”.
Author details
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet,
Box 280, Stockholm SE-17177, Sweden. 2Department of Microbiology, Faculty
of Life Sciences, University of Balochistan, Quetta, Pakistan. 3Department of
Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ),
69120 Heidelberg, Germany. 4Oncovirology Laboratory, Institut Pasteur du
Maroc, 20360 Casablanca, Morocco. 5Cancer Bio-Immunotherapy Unit Centro
di Riferimento Oncologico IRCCS - National Cancer Institute, Via Franco
Gallini, 233081 Aviano, PN, Italy. 6University Hassan II, Faculty of Sciences and
Techniques, Mohammedia - Casablanca, Laboratory of Virology, Microbiology
and Quality/ETB, Mohammedia, BP 14620650, Morocco. 7Department of
Orolaryngology – Head and Neck Surgery, First Affiliated Hospital of Guangxi
Medical University, Guangxi, People’s Republic of China.
Received: 19 May 2015 Accepted: 31 July 2015
References
1. Licitra L, Bernier J, Cvitkovic E, Grandi C, Spinazze S, Bruzzi P, et al. Cancer of
the nasopharynx. Crit Rev Oncol Hematol. 2003;45(2):199–213.
2. Shanmugaratnam K, Sobin LH. The World Health Organization histological
classification of tumours of the upper respiratory tract and ear. A commentary
on the second edition. Cancer. 1993;71(8):2689–97.3. Tabuchi K, Nakayama M, Nishimura B, Hayashi K, Hara A. Early detection of
nasopharyngeal carcinoma. Int J Otolaryngology. 2011;2011:638058.
doi:10.1155/2011/638058.
4. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal
carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1765–77.
doi:10.1158/1055-9965.EPI-06-0353.
5. Armstrong RW, Kannan Kutty M, Dharmalingam SK, Ponnudurai JR.
Incidence of nasopharyngeal carcinoma in Malaysia, 1968–1977. Br J Cancer.
1979;40(4):557–67.
6. Devi BC, Pisani P, Tang TS, Parkin DM. High incidence of nasopharyngeal
carcinoma in native people of Sarawak, Borneo Island. Cancer Epidemiol
Biomarkers. 2004;13(3):482–6.
7. Lee AW, Foo W, Mang O, Sze WM, Chappell R, Lau WH, et al. Changing
epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year
period (1980–99): an encouraging reduction in both incidence and mortality.
Int JCancer J. 2003;103(5):680–5. doi:10.1002/ijc.10894.
8. Chaouki N, el Gueddari B. Epidemiological descriptive approach of cancer in
Morocco through the activity of the National Institute of Oncology. 1986–7.
Bull Cancer. 1991;78(7):603–9.
9. Bouchbika Z, Haddad H, Benchakroun N, Eddakaoui H, Kotbi S, Megrini A, et al.
Cancer incidence in Morocco: report from Casablanca registry 2005–2007. Pan
African Med J. 2013;16:31. doi:10.11604/pamj.2013.16.31.2791.
10. Benider A, Sahraoui S, Acharki A, Samlali R, Kahlain A. Carcinomas of the
nasopharynx in children. Analysis of 50 cases. Bull Cancer. 1995;82(2):155–61.
11. Ellouz R, Cammoun M, Attia RB, Bahi J. Nasopharyngeal carcinoma in
children and adolescents in Tunisia: clinical aspects and the paraneoplastic
syndrome. IARC Sci Publ. 1978;20:115–29.
12. Chow KC, Ma J, Lin LS, Chi KH, Yen SH, Liu SM, et al. Serum responses
to the combination of Epstein-Barr virus antigens from both latent and
acute phases in nasopharyngeal carcinoma: complementary test of
EBNA-1 with EA-D. Cancer Epidemiol Biomarkers Prev. 1997;6(5):363–8.
13. Huang TB. Cancer of the nasopharynx in childhood. Cancer. 1990;66(5):968–71.
14. Burt RD, Vaughan TL, McKnight B. Descriptive epidemiology and survival
analysis of nasopharyngeal carcinoma in the United States. Int J Cancer.
1992;52(4):549–56.
15. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer
Biol. 2002;12(6):421–9.
16. Jia WH, Luo XY, Feng BJ, Ruan HL, Bei JX, Liu WS, et al. Traditional Cantonese
diet and nasopharyngeal carcinoma risk: a large-scale case–control study in
Guangdong China. BMC cancer. 2010;10:446. doi:10.1186/1471-2407-10-446.
17. Yu MC, Mo CC, Chong WX, Yeh FS, Henderson BE. Preserved foods and
nasopharyngeal carcinoma: a case–control study in Guangxi China. Cancer
Res. 1988;48(7):1954–9.
18. Yuan JM, Wang XL, Xiang YB, Gao YT, Ross RK, Yu MC. Preserved foods in
relation to risk of nasopharyngeal carcinoma in Shanghai, China. Int J
Cancer. 2000;85(3):358–63.
19. Nguyen-Van D, Ernberg I, Phan-Thi Phi P, Tran-Thi C, Hu L. Epstein-Barr
virus genetic variation in Vietnamese patients with nasopharyngeal
carcinoma: full-length analysis of LMP1. Virus Genes. 2008;37(2):273–81.
doi:10.1007/s11262-008-0262-9.
20. Niedobitek G. Epstein-Barr virus infection in the pathogenesis of
nasopharyngeal carcinoma. Molecular Pathology. 2000;53(5):248–54.
21. Ayadi W, Khabir A, Hadhri-Guiga B, Fki L, Toumi N, Siala W, et al. North
African and Southeast Asian nasopharyngeal carcinomas: between the
resemblance and the dissemblance. Bull Cancer. 2010;97(4):475–82.
doi:10.1684/bdc.2010.1090.
22. Wei WI, Kwong DL. Current management strategy of nasopharyngeal
carcinoma. Clinical Exp Otorhinolaryngology. 2010;3(1):1–12.
doi:10.3342/ceo.2010.3.1.1.
23. Agulnik M, Siu LL. State-of-the-art management of nasopharyngeal
carcinoma: current and future directions. Br J Cancer. 2005;92(5):799–806.
doi:10.1038/sj.bjc.6602449.
24. Yip TT, Ngan RK, Fong AH, Law SC. Application of circulating plasma/serum
EBV DNA in the clinical management of nasopharyngeal carcinoma. Oral
Oncol. 2014;50(6):527–38. doi:10.1016/j.oraloncology.2013.12.011.
25. Chi KH, Chang YC, Guo WY, Leung MJ, Shiau CY, Chen SY, et al. A phase III
study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma
patients. Int J Radiat Oncol Biol Phys. 2002;52(5):1238–44.
26. Loyo M, Brait M, Kim MS, Ostrow KL, Jie CC, Chuang AY, et al. A survey of
methylated candidate tumor suppressor genes in nasopharyngeal
carcinoma. Int J Cancer. 2011;128(6):1393–403. doi:10.1002/ijc.25443.
Nawaz et al. Clinical Epigenetics  (2015) 7:89 Page 11 of 1227. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, Kinzler
KW. Cancer genome landscapes. Science. 2013;339(6127):1546–58.
doi:10.1126/science.1235122.
28. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of
human cancer. Nat Rev Genet. 2006;7(1):21–33. doi:10.1038/nrg1748.
29. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung
cancer. Nat Rev Cancer. 2004;4(9):707–17. doi:10.1038/nrc1432.
30. Lee SM, Park JY, Kim DS. Wif1 hypermethylation as unfavorable
prognosis of non-small cell lung cancers with EGFR mutation. Mol Cells.
2013;36(1):69–73. doi:10.1007/s10059-013-0060-7.
31. Kaneda A, Matsusaka K, Aburatani H, Fukayama M. Epstein-Barr virus
infection as an epigenetic driver of tumorigenesis. Cancer Res.
2012;72(14):3445–50. doi:10.1158/0008-5472.CAN-11-3919.
32. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell.
2004;5(5):423–8.
33. Tsao SW, Yip YL, Tsang CM, Pang PS, Lau VM, Zhang G, et al. Etiological
factors of nasopharyngeal carcinoma. Oral Oncol. 2014;50(5):330–8.
doi:10.1016/j.oraloncology.2014.02.006.
34. Li LL, Shu XS, Wang ZH, Cao Y, Tao Q. Epigenetic disruption of cell signaling
in nasopharyngeal carcinoma. Chin J Cancer. 2011;30(4):231–9.
35. Tsao SW, Tsang CM, Pang PS, Zhang G, Chen H, Lo KW. The biology of EBV
infection in human epithelial cells. Semin Cancer Biol. 2012;22(2):137–43.
36. Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal
carcinoma. Semin Cancer Biol. 2002;12(6):451–62.
37. Flower K, Thomas D, Heather J, Ramasubramanyan S, Jones S, Sinclair AJ.
Epigenetic control of viral life-cycle by a DNA-methylation dependent
transcription factor. PLoS One. 2011;6(10):e25922. doi:10.1371/
journal.pone.0025922.
38. Kwok WK, Pang JC, Lo KW, Ng HK. Role of the RARRES1 gene in
nasopharyngeal carcinoma. Cancer Genet Cytogenet. 2009;194(1):58–64.
doi:10.1016/j.cancergencyto.2009.06.005.
39. Tian F, Yip SP, Kwong DL, Lin Z, Yang Z, Wu VW. Promoter
hypermethylation of tumor suppressor genes in serum as potential
biomarker for the diagnosis of nasopharyngeal carcinoma. Cancer
Epidemiol. 2013;37(5):708–13. doi:10.1016/j.canep.2013.05.012.
40. Takacs M, Segesdi J, Banati F, Koroknai A, Wolf H, Niller HH, et al. The
importance of epigenetic alterations in the development of Epstein-Barr
virus-related lymphomas. Mediterr J Hematol Infect Dis. 2009;1(2):e2009012.
doi:10.4084/MJHID.2009.012.
41. Seo SY, Kim EO, Jang KL. Epstein-Barr virus latent membrane protein 1
suppresses the growth-inhibitory effect of retinoic acid by inhibiting
retinoic acid receptor-beta2 expression via DNA methylation. Cancer Lett.
2008;270(1):66–76. doi:10.1016/j.canlet.2008.04.043.
42. Lung ML, Cheung AK, Ko JM, Lung HL, Cheng Y, Dai W. The interplay
of host genetic factors and Epstein-Barr virus in the development of
nasopharyngeal carcinoma. Chin J Cancer. 2014;33(11):556–68.
doi:10.5732/cjc.014.10170.
43. Saito M, Nishikawa J, Okada T, Morishige A, Sakai K, Nakamura M, et al. Role
of DNA methylation in the development of Epstein-Barr virus-associated
gastric carcinoma. J Med Virol. 2013;85(1):121–7. doi:10.1002/jmv.23405.
44. Zhao J, Liang Q, Cheung KF, Kang W, Lung RW, Tong JH, et al.
Genome-wide identification of Epstein-Barr virus-driven promoter
methylation profiles of human genes in gastric cancer cells. Cancer.
2013;119(2):304–12. doi:10.1002/cncr.27724.
45. Matsusaka K, Kaneda A, Nagae G, Ushiku T, Kikuchi Y, Hino R, et al.
Classification of Epstein-Barr virus-positive gastric cancers by definition of
DNA methylation epigenotypes. Cancer Res. 2011;71(23):7187–97.
doi:10.1158/0008-5472.CAN-11-1349.
46. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific
PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl
Acad Sci U S A. 1996;93(18):9821–6.
47. Hutajulu SH, Indrasari SR, Indrawati LP, Harijadi A, Duin S, Haryana SM,
et al. Epigenetic markers for early detection of nasopharyngeal
carcinoma in a high risk population. Mol Cancer. 2011;10:48.
doi:10.1186/1476-4598-10-48.
48. Zhang Z, Sun D, Hutajulu SH, Nawaz I, Van Nguyen D, Huang G, et al.
Development of a non-invasive method, multiplex methylation specific PCR
(MMSP), for early diagnosis of nasopharyngeal carcinoma. PLoS One.
2012;7(11):e45908. doi:10.1371/journal.pone.0045908.
49. Hu LF, Minarovits J, Cao SL, Contreras-Salazar B, Rymo L, Falk K, et al.
Variable expression of latent membrane protein in nasopharyngealcarcinoma can be related to methylation status of the Epstein-Barr virus
BNLF-1 5′-flanking region. J Virol. 1991;65(3):1558–67.
50. Chang YS, Tyan YS, Liu ST, Tsai MS, Pao CC. Detection of Epstein-Barr virus
DNA sequences in nasopharyngeal carcinoma cells by enzymatic DNA
amplification. J Clin Microbiol. 1990;28(11):2398–402.
51. Wu TC, Mann RB, Epstein JI, MacMahon E, Lee WA, Charache P, et al.
Abundant expression of EBER1 small nuclear RNA in nasopharyngeal
carcinoma. A morphologically distinctive target for detection of Epstein-Barr
virus in formalin-fixed paraffin-embedded carcinoma specimens. Am J
Pathol. 1991;138(6):1461–9.
52. Chen CL, Wen WN, Chen JY, Hsu MM, Hsu HC. Detection of Epstein-Barr
virus genome in nasopharyngeal carcinoma by in situ DNA hybridization.
Intervirology. 1993;36(2):91–8.
53. Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N.
Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the
nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol.
1995;146(6):1355–67.
54. Lee WY, Hsiao JR, Jin YT, Tsai ST. Epstein-Barr virus detection in neck
metastases by in-situ hybridization in fine-needle aspiration cytologic
studies: an aid for differentiating the primary site. Head Neck.
2000;22(4):336–40.
55. Tsai ST, Jin YT, Su IJ. Expression of EBER1 in primary and metastatic
nasopharyngeal carcinoma tissues using in situ hybridization. A correlation
with WHO histologic subtypes. Cancer. 1996;77(2):231–6. doi:10.1002/
(SICI)1097-0142(19960115)77:2<231::AID-CNCR2>3.0.CO;2-P.
56. Macdonald MR, Freeman JL, Hui MF, Cheung RK, Warde P, McIvor NP,
et al. Role of Epstein-Barr virus in fine-needle aspirates of metastatic
neck nodes in the diagnosis of nasopharyngeal carcinoma. Head Neck.
1995;17(6):487–93.
57. Chao TY, Chow KC, Chang JY, Wang CC, Tsao TY, Harn HJ, et al. Expression
of Epstein-Barr virus-encoded RNAs as a marker for metastatic
undifferentiated nasopharyngeal carcinoma. Cancer. 1996;78(1):24–9.
doi:10.1002/(SICI)1097-0142(19960701)78:1<24::AID-CNCR5>3.0.CO;2-H.
58. Agulnik M, Epstein JB. Nasopharyngeal carcinoma: current management,
future directions and dental implications. Oral Oncol. 2008;44(7):617–27.
doi:10.1016/j.oraloncology.2007.08.003.
59. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile
of human cancer. Cancer Res. 2001;61(8):3225–9.
60. Fernandez AF, Rosales C, Lopez-Nieva P, Grana O, Ballestar E, Ropero S, et al.
The dynamic DNA methylomes of double-stranded DNA viruses associated
with human cancer. Genome Res. 2009;19(3):438–51. doi:10.1101/
gr.083550.108. gr.083550.108 [pii].
61. Challouf S, Ziadi S, Zaghdoudi R, Ksiaa F, Ben Gacem R, Trimeche M.
Patterns of aberrant DNA hypermethylation in nasopharyngeal carcinoma in
Tunisian patients. Clin Chim Acta. 2012;413(7–8):795–802. doi:10.1016/
j.cca.2012.01.018.
62. Li L, Zhang Y, Fan Y, Sun K, Su X, Du Z, et al. Characterization of the
nasopharyngeal carcinoma methylome identifies aberrant disruption of key
signaling pathways and methylated tumor suppressor genes. Epigenomics.
2015;7(2):155–73. doi:10.2217/epi.14.79.
63. Lo KW, Chung GTY, To KF. Acquired genetic and epigenetic alterations in
nasopharyngeal carcinoma. Nasopharyngeal carcinoma: keys for translational
medicine and biology. USA: Springer Science + Business Media; 2013.
64. Singh P, Chen C, Pal-Ghosh S, Stepp MA, Sheppard D, Van De Water L.
Loss of integrin alpha9beta1 results in defects in proliferation, causing
poor re-epithelialization during cutaneous wound healing. J Invest
Dermatol. 2009;129(1):217–28. doi:10.1038/jid.2008.201.
65. Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, et al. High frequency of
promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
Cancer Res. 2001;61(10):3877–81.
66. Wang T, Liu H, Chen Y, Liu W, Yu J, Wu G. Methylation associated
inactivation of RASSF1A and its synergistic effect with activated K-Ras in
nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2009;28:160.
doi:10.1186/1756-9966-28-160.
67. Liggett Jr WH, Sidransky D. Role of the p16 tumor suppressor gene in
cancer. J Clin Oncol. 1998;16(3):1197–206.
68. Lo KW, Cheung ST, Leung SF, van Hasselt A, Tsang YS, Mak KF, et al.
Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer
Res. 1996;56(12):2721–5.
69. Ayadi W, Karray-Hakim H, Khabir A, Feki L, Charfi S, Boudawara T, et al.
Aberrant methylation of p16, DLEC1, BLU and E-cadherin gene promoters in
Nawaz et al. Clinical Epigenetics  (2015) 7:89 Page 12 of 12nasopharyngeal carcinoma biopsies from Tunisian patients. Anticancer Res.
2008;28(4B):2161–7.
70. Chan KH, Gu YL, Ng F, Ng PS, Seto WH, Sham JS, et al. EBV specific
antibody-based and DNA-based assays in serologic diagnosis of
nasopharyngeal carcinoma. Int J Cancer. 2003;105(5):706–9.
doi:10.1002/ijc.11130.
71. Ng WT, Choi CW, Lee MC, Chan SH, Yau TK, Lee AW. Familial
nasopharyngeal carcinoma in Hong Kong: epidemiology and implication in
screening. Fam Cancer. 2009;8(2):103–8. doi:10.1007/s10689-008-9213-9.
72. Stebbing J, Bower M, Syed N, Smith P, Yu V, Crook T. Epigenetics: an
emerging technology in the diagnosis and treatment of cancer.
Pharmacogenomics. 2006;7(5):747–57. doi:10.2217/14622416.7.5.747.
73. Deng ZW, Li YYB, Sun HC, Yao TH. Infection of nasopharyngeal carcinoma
cells (CNE line) with Epstein-Barr virus. Acta Biologie Experimentalis Sinica.
1981;14(1):271–4.
74. Lawrence JB, Villnave CA, Singer RH. Sensitive, high-resolution chromatin
and chromosome mapping in situ: presence and orientation of two closely
integrated copies of EBV in a lymphoma line. Cell. 1988;52(1):51–61.
75. Whitaker AM. The chromosomes of the Namalwa cell line. J Biol Stand.
1985;13(2):173–5.
76. Kamranvar SA, Gruhne B, Szeles A, Masucci MG. Epstein-Barr virus promotes
genomic instability in Burkitt’s lymphoma. Oncogene. 2007;26(35):5115–23.
doi:10.1038/sj.onc.1210324.
77. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs.
Bioinformatics. 2002;18(11):1427–31.
78. Habeshaw G, Yao QY, Bell AI, Morton D, Rickinson AB. Epstein-Barr virus
nuclear antigen 1 sequences in endemic and sporadic Burkitt’s lymphoma
reflect virus strains prevalent in different geographic areas. J Virol.
1999;73(2):965–75.
79. Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, et al. Methylation of
multiple genes as a candidate biomarker in non-small cell lung cancer.
Cancer Lett. 2011;303(1):21–8. doi:10.1016/j.canlet.2010.12.011.
80. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, et al.
Discovery of novel targets for aberrant methylation in pancreatic carcinoma
using high-throughput microarrays. Cancer Res. 2003;63(13):3735–42.
81. Xiao X, Zhao W, Tian F, Zhou X, Zhang J, Huang T, et al. Cytochrome b5
reductase 2 is a novel candidate tumor suppressor gene frequently
inactivated by promoter hypermethylation in human nasopharyngeal
carcinoma. Tumor Biol. 2014; 35(4):3755–3763.
82. Zhou X. The establishment of methylation profile of nasopharyngeal
carcinoma [masters]. Guangxi: Guangxi Medical University; 2009.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
